ABSTRACT Synthetic 3-phosphocitrate, an extremely potent inhibitor of calcium phosphate crystallization as determined in a nonbiological physical-chemical assay, has many similarities to a mitochondrial factor that inhibits crystallization of nondiffracting amorphous calcium phosphate. In order to determine whether phosphocitrate can prevent uptake and crystallization of calcium phosphate in mitochondria in vivo, it was administered intraperitoneally to animals given large daily doses of calcium gluconate or parathyroid hormone, a regimen that causes massive accumulation and crystallization of calcium phosphate in the mitochondria and cytosol of renal tubule cells in vivo. Administration of phosphocitrate greatly reduced the net uptake of Ca2" by the kidneys and prevented the appearance of apatite-like crystalline structures within the mitochondrial matrix and cytosol of renal tubule cells. Phosphocitrate, which is a poor chelator of Ca2", did not reduce the hypercalcemia induced by either agent. These in vivo observations therefore indicate that phosphocitrate acts primarily at the cellular level to prevent the extensive accumulation of calcium phosphate in kidney cells by inhibiting the mitochondrial accumulation or crystallization of calcium phosphate.
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Previous reports from this laboratory have described the occurrence of a factor in rat liver mitochondria that inhibits the in vitro conversion of amorphous calcium phosphate to crystalline forms such as hydroxyapatite (1) (2) (3) (4) (5) (6) . A factor or factors with similar properties also are present in the hepatopancreas of the blue crab Callinectes sapidus which salvages and stores large amounts of calcium phosphate in a nondiffracting form during ecdysis (7, 8) . Other factors that inhibit precipitation or crystallization of calcium salts have also been demonstrated in urine, saliva, bile, and other body fluids (9) (10) (11) (12) (13) (14) , where they have been proposed to maintain high concentrations ofCa2" and phosphate in solutions in apparent excess ofthe solubility product ofcalcium phosphate and other relatively insoluble calcium salts. The mitochondrial factor has many similarities with 3- phosphocitrate, prepared synthetically in this laboratory, with respect to molecular weight, chromatographic behavior, and mass spectrum (15) . Moreover, synthetic phosphocitrate was found to be the most potent known inhibitor of the growth of hydroxyapatite crystals from supersaturated calcium phosphate solutions at pH 7.4, as determined in an in vitro crystal growth assay system (15) .
This communication reports experiments designed to determine whether phosphocitrate administration can inhibit mitochondrial calcium phosphate deposition or crystallization in intact tissues in vivo in two well-studied animal models in which acute calcification of the kidney was induced by administration of calcium gluconate to rats (16, 17) and of excess parathyroid hormone (PTH) to mice (16, 17) . Both agents have been shown to cause hypercalcemia, a large increase in the calcium content of the kidneys, and deposition of electron-dense granules of insoluble and often crystalline calcium salts within the mitochondria of tubule cells, followed by extensive extramitochondrial precipitation of calcium salts, a chain of events that eventually results in cell necrosis.
MATERIALS AND METHODS
The two experimental models ofkidney calcification used in this investigation were chosen because they have been extensively studied and yield severe nephrocalcinosis in a few days. Kidney calcification was induced in young male CD rats (50-60 g, Charles River Breeding Laboratories) by administration of calcium gluconate (16, 17) . The animals were fed standard chow and water ad lib throughout the experimental period. They were divided into two groups, a control group receiving daily intraperitoneal injections of isotonic saline and an experimental group receiving daily intraperitoneal injections of phosphocitrate. One hour after each of these injections, all animals were given 1.0 ml of 10% calcium gluconate intraperitoneally. The amounts of phosphocitrate administered are given in the figure legends. Twenty-four hours after the 3rd, 5th, 7th and 10th injections of calcium gluconate, animals from both groups were anesthetized with sodium pentobarbital, blood was withdrawn from the inferior vena cava for analysis, and both kidneys were removed for microscopic examination and determination of their calcium content.
Renal calcification was induced in young male Swiss mice (15-18 g, Buckberg Laboratories, Tomkins Cove, NY) by administration of excess parathyroid hormone. The mice were divided into two groups that received daily intraperitoneal injections of either isotonic saline (controls) or phosphocitrate (experimental group), followed 1 hr later by injection of50 units (USP) of the hormone (Eli Lilly). Details of the phosphocitrate dosage are given in the figure legends. Animals from both groups were sacrificed 24 hr after the first, second, third, and fourth hormone injections, blood was withdrawn from the inferior vena cava for calcium analysis, and both kidneys were removed for measurement of calcium accumulation and microscopic examination.
For determination of calcium content of the kidneys, midcoronal sections were weighed, homogenized by sonication in 5.0 ml of a butanol/HCl/La3+ mixture (5.85 g of La203, 25 ml of concentrated HCl, and 40 ml of n-butanol, diluted to 1 liter with deionized water), and centrifuged (10,000 X g for 10 min) to remove insoluble matter (18) . Calcium in the supernatant fraction was determined with a model 251 Instrumentation Laboratory atomic absorption spectrophotometer. Total serum calcium was measured by atomic absorption in 10-tLd serum samples diluted to 1.0 ml with the butanol/HC/La3+ mixture (19) .
Abbreviation: PTH, parathyroid hormone.
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Representative kidney sections were retained for microscopic verification ofcalcification and ultrastructural examination with a Zeiss 10B electron microscope. Details of tissue preparation are given in figure legends.
Phosphocitric acid was synthesized from triethylcitrate and o-phenylene phosphorochloridate as described and purified by anion exchange chromatography (15) . Stock solutions of phosphocitric acid were converted to the sodium salt before use by neutralization with NaOH. The concentration ofphosphocitrate was determined enzymatically (15) . RESULTS Effect of Phosphocitrate Administration on Kidney Calcification Induced by Calcium Gluconate and PTH. Intraperitoneal administration of small quantities of phosphocitrate effectively inhibited the severe kidney calcification produced by administration ofcalcium gluconate in rats and by PTH in mice. In the calcium gluconate animals, the calcium content of the kidneys increased 70-fold, from a normal level of 2 AmoVg tissue to a mean (± SD) of140 ± 32 ,gmoVg over the 10-day period ( Fig. 1) . The kidney calcification produced in mice by excess PTH administration was qualitatively similar to that produced by calcium gluconate, although it became manifest over a shorter time period. Kidney calcium levels increased from 2 1umoVg tissue to 60 ± 10 Amol/g by day 4 of hormone administration. Kidney calcification induced by these agents progressed as described (10, 11) . In contrast, the kidneys from animals receiving intraperitoneal injections of phosphocitrate (60 Zmol/kg) prior to administration of calcium gluconate or PTH showed a delayed and greatly decreased calcium uptake over the same period (Fig.  1) . The mean calcium content ofthe kidneys ofanimals receiving phosphocitrate was only 10 + 5 ,umol/g tissue by day 4 of the PTH treatment and 37 ± 13 umoVg tissue by day 10 of the calcium gluconate treatment. In both groups these values represent a significant reduction in tissue calcium content relative to the control animals. In identical control experiments, intraperitoneal administration ofsodium citrate or sodium phosphate (60 ,umoVkg) in place ofphosphocitrate had no detectable effect on the development ofkidney calcification produced by calcium gluconate or PTH.
Serum Calcium Levels. Measurements ofserum calcium levels showed that hypercalcemia prevailed throughout the experimental period in both the calcium gluconate-and PTHtreated animals, but in neither group was the hypercalcemia diminished by phosphocitrate administration. Total serum calcium increased from a normal level of 1.8 mM to > 3.0 mM and iemained high throughout the experimental period in all groups, with no significant differences upon phosphocitrate administration.
Direct measurement offree ionized Ca2" in the serum samples with a calibrated Ca2'-selective electrode showed increased but essentially equal Ca2" activities in all groups. These measurements thus indicate that phosphocitrate administration does not result in sequestration of the increased serum Ca2" in the form ofunionized complexes or chelates. Other experiments (unpublished data) have shown that phosphocitrate is only weakly active as a chelating agent for Ca2" at pH 7.4. The apparent formation constant ofCa2+ phosphocitrate complex is not high enough to affect significantly the serum levels offree Ca2" at the doses of phosphocitrate administered.
Response to Phosphocitrate Dose. Inhibition of PTH-induced renal calcification was observed at all levels of phosphocitrate tested (Fig. 2) , from 0.075 to 3.0 jumol/day. Although the higher doses were more effective in preventing nephrocal- 
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Light Microscopy. Microscopic examination of kidney sections from control animals receiving calcium gluconate or PTH showed a progressive increase in deposition of calcium phosphate over the experimental period, as indicated by the von Kossa stain (20) . Although the lesions progressed more rapidly in the PTH treated group than in the calcium gluconate group, the overall patterns of mineralization were qualitatively similar in the two models. In the control group receiving calcium gluconate, no deposition ofcalcium salts was observed in the proximal tubule areas through day 5 of treatment. On day 7, small areas of calcification were observed along the basement membrane of the proximal tubules, and by day 10 all sections examined showed extensive mineralization in the proximal tubule area similar to that described in earlier reports ofacute calcium gluconate nephrotoxicity (21) . In some areas the calcification was so extensive that no cellular detail could be discerned. Much cellular debris and mineralized material was also present in the tubular lumens.
A similar course of calcification was observed in the control animals treated with PTH. No calcium deposits were observed in the kidneys of the mice 1 day after the first PTH injection. Twenty-four hours after the second PTH injection, small sites of mineralization were evident in the proximal tubule area. Large areas ofcalcification were observed after the fourth PTH injection, along with many necrotic cells along the lumen ofthe A proximal tubules (Fig. 3 ), in agreement with previous reports (16, 17) .
Kidney sections from animals receiving phosphocitrate together with calcium gluconate or PTH were remarkably free from obvious calcium deposits. The von Kossa stain (20) for calcium salts was completely negative in the tubular area of the kidneys ofall animals treated with calcium gluconate and phosphocitrate through day 7. Only a few sections contained small areas of calcium deposition by day 10. Similarly, no calcium deposits appeared in the PTH/phosphocitrate group until day 4, and then only a few very small deposits were found (Fig. 3) .
Electron Microscopic Examination. In confirmation of the observations by light microscopy, the kidneys of the control animals receiving calcium gluconate or PTH showed calcification changes on electron microscopic examination that were in close agreement with earlier reports (16, 17) on ultrastructural changes in nephrocalcinosis induced by these agents. The earliest evidence of calcium accumulation in the kidneys of the control animals was the appearance of very dense granules within the mitochondria of the proximal tubular cells; these were first observed on day 3 with calcium gluconate and on day 2 with PTH. As the lesions progressed, the number of dense granular deposits within the mitochondria increased in approximate proportion to the increase in total calcium content of the kidneys. By day 7 of the calcium gluconate regimen and day 3 of PTH, the mitochondria were filled with dense mineral deposits, the intracristal spaces were dilated, and many tubule cells were noticeably swollen. In the most severely damaged cells the mitochondria were rounded and swollen, and contained numerous granular dense bodies within the matrix; there was extensive cytoplasmic swelling and apparent rupture of plasma membranes. In some cells the mitochondria contained apatite-like spicules, usually associated with the cristae. On day 10 of calcium gluconate or day 4 of PTH administration the mitochondria were heavily calcified, and extensive mineral deposits appeared in the extramitochondrial cytoplasm (Fig. 4) . At this stage, many of the mitochondria had lost their characteristic shape and appeared as rounded bodies full ofapatite-like crystalline structures.
Similar examination of kidney tissue from animals given phosphocitrate prior to calcium gluconate or PTH revealed few intracellular abnormalities within the proximal tubular area. In most of the tissue sections examined at the end of the experimental periods, there was slight mitochondrial swelling (Fig.  4) . In only a few highly localized areas were intramitochondrial or cytosolic mineral deposits observed. Tissue sections from the phosphocitrate-treated animals were otherwise unremarkable. uptake of equivalent amounts of phosphate (22, 23) . Endoplasmic reticulum of the liver, on the other hand, has the capacity to segregate only a few nanomoles ofCa2" per mg ofprotein (24) . Because accumulation of even small amounts of Ca2+ and phosphate within the small volume of the mitochondrial matrix will exceed the solubility product of brushite (CaHPO4) or tricalcium phosphate Ca3(PO4)2, insoluble deposits of one or both of these salts is likely to result.
Calcium phosphate deposits in normal rat liver mitochondria loaded in vitro are amorphous and show no crystalline x-ray diffraction pattern (24, 25) . On microincineration at 900TC, however, they are converted into residues that show the characteristic diffraction pattern ofhydroxyapatite (26, 27) . Because amorphous precipitates of calcium phosphate spontaneously undergo crystallization at pH 7.4 and 37TC within minutes, it has been postulated (1-6) that the amorphous calcium phosphate deposits in mitochondria are kept from crystallizing into apatite or other crystalline forms by the presence ofendogenous inhibitors within the mitochondrial matrix.
It is possible that the capacity of mitochondrial inhibitors to prevent crystallization of matrix deposits of amorphous calcium phosphate may be exceeded when abnormally large amounts of calcium and phosphate pass into the mitochondrial matrix, as occurs during administration of excess calcium gluconate or PTH. Once such deposits become crystalline they also become less soluble, dissolve more slowly, and serve as nuclei for further growth. The growth and accumulation of such crystals could result in irreversible damage to the mitochondrial inner membrane and its Ca2+-concentrating capacity. Crystallization of hydroxyapatite in the extramitochondrial cytoplasm then may ensue as the plasma membrane becomes more permeable and allows Ca2+ and phosphate to pass into the cell more freely.
It appears possible that phosphocitrate administered as described here prevents or greatly retards such a sequence of events by gaining entrance into the renal tubule cells and, further, into their mitochondria to supplement the action of endogenous mitochondrial factors in retarding crystallization. It is also possible that phosphocitrate may act primarily in the cytosol or at the plasma membrane. Examination ofthe organ and intracellular distribution ofadministered phosphocitrate should yield information as to the site of its action in suppressing renal calcification. In any case, its action is other than as a Ca2+-chelating agent; this is also shown by data in Fig. 3 (15) . Although diphosphonates were found to be effective in preventing clinical nephrocalcinosis (29) , they are toxic to normal calcification processes in the periosteum and epiphyseal disks oflong bones (30) . Comparative studies with ethane-l-hydroxy-1,1-diphosphonate as a control have shown that daily administration ofphosphocitrate (60 Amol/kg) for up to 14 days to rats and mice had no apparent effect on normal bone development and growth plate structure, in contrast to the inhibition ofnormal calcification produced by the diphosphonate over the same period (unpublished data). Other studies have shown that phosphocitrate has no effect on in vivo calcification in a matrix-induced model ofbone formation (31) . Further investigation is necessary, but it appears possible that phosphocitrate functions primarily to inhibit ectopic or pathological calcification selectively.
